The collaboration allows clinicians to order the Galleri test and view results directly within existing electronic health record workflows.

GRAIL and Epic have announced a collaboration to integrate the Galleri multi-cancer early detection (MCED) test into the Epic electronic health record (EHR) platform. The integration, delivered through Epic Aura, is designed to expand access to the test across approximately 450 health systems in the US.

The integration allows healthcare providers to order the Galleri test at the point of care, receive results, and manage patient follow-up within their native EHR environment. By embedding the test into existing clinical workflows, the companies aim to reduce administrative burdens and manual processes for clinicians and laboratory staff.

“Today, recommended screening exists for only five cancers in the US, yet more than 70% of deaths are caused by cancers without a recommended screening test,” says Josh Ofman, MD, MSHS, president at GRAIL, in a release. “With a scalable integration through Epic, we are reducing operational barriers and making it easier for healthcare providers to incorporate the Galleri test into routine care, with the ultimate goal of supporting early cancer detection before symptoms appear, when outcomes may be better.”

Implementation and Workflow Alignment

Implementation planning for the integration began in the first quarter of 2026, including early adopter programs. GRAIL is working with Epic and Amazon Web Services, its preferred cloud provider, to support workflow alignment, training, and deployment success. Broad availability for health systems, community healthcare providers, and retail health clinics is expected by the end of 2026.

“Aura helps healthcare organizations collaborate by removing administrative barriers,” says Alan Hutchison, vice president at Epic, in a release. “With GRAIL joining the Epic community, together with healthcare organizations, we can advance early detection and ultimately improve cancer survival rates.”

Philip Oravetz, MD, chief population health officer at Ochsner Health, says that embedding the test within existing EHR infrastructure supports appropriate patient identification and streamlines ordering within established workflows. This approach is intended to enhance the patient experience and improve care delivery for population-focused health care.

Test Performance and Regulatory Status

The Galleri test uses a blood draw to detect signals for more than 50 types of cancer before symptoms appear. It is intended for use in adults with an elevated risk for cancer, such as those aged 50 or older, and should be used in addition to routine screenings like mammography, colonoscopy, or cervical cancer screening. The test is not a substitute for a thorough clinical evaluation and must be ordered by a licensed healthcare provider.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 and accredited by the College of American Pathologists. The Galleri test has not been cleared or approved by the Food and Drug Administration. The laboratory is regulated under CLIA to perform high-complexity testing.

ID 450232488 © Andrei Rahalski | Dreamstime.com

Related Reading: